José María Moraleda Jiménez-rekin lankidetzan egindako argitalpenak (22)

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2019

  1. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

    Blood, Vol. 134, Núm. 16, pp. 1337-1345

2011

  1. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

    Blood, Vol. 118, Núm. 3, pp. 529-534

2006

  1. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

2003

  1. High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group

    Annals of Oncology, Vol. 14, Núm. 1, pp. 140-151

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

  2. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma

    British Journal of Haematology, Vol. 109, Núm. 1, pp. 138-147

  3. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

    British Journal of Haematology, Vol. 109, Núm. 2, pp. 438-446

1997

  1. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors

    Bone Marrow Transplantation, Vol. 20, Núm. 6, pp. 451-458

1991

  1. Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes

    Medicina clínica, Vol. 97, Núm. 10, pp. 369-372

1990

  1. Non-traumatic rupture of the spleen in malignant hemopathies. 2 new cases

    Sangre, Vol. 35, Núm. 6, pp. 477-479

  2. Surface phenotype and immunoglobulin levels in B-cell chronic lymphocytic leukaemia.

    Haematologia, Vol. 23, Núm. 1, pp. 49-56

1988

  1. Linfomas no-hodgkinianos. II. Factores pronósticos.

    Sangre, Vol. 33, Núm. 5, pp. 367-371

  2. Non-Hodgkin's lymphoma. I. Clinicobiological characteristics in a series of 98 patients

    Sangre, Vol. 33, Núm. 5, pp. 361-366

  3. Treatment of high-risk acute lymphoblastic leukemia with protocols PETHEMA LAL 7/78 and LAL 17/84

    Anales Espanoles de Pediatria, Vol. 29, Núm. SUPPL. 34, pp. 72-83

1987

  1. Síndromes mielodisplásicos: caracterización de una serie de 56 pacientes clasificados según criterios FAB.

    Sangre, Vol. 32, Núm. 4, pp. 436-444

1986

  1. Bone marrow necrosis and treatment with Interferon

    Journal of Clinical Pathology

1985

  1. Immunological markers of peripheral blood and lymph node lymphocytes in Hodgkin's disease

    Neoplasma, Vol. 32, Núm. 2, pp. 191-198